Aminoglycosides use in patients over 75 years old

Age and Ageing

Volumn 43, Issue 5, 2014, Pages 676-681

  Fraisse, Thibaut ^a   Gras aygon, Claudine ^a   Paccalin, Marc ^b   Vitrat, Virginie ^c   De wazieres, Benoit ^d   Baudoux, Veronique ^e   Lechiche, Catherine ^d   Vicens, Aurelie ^f   Sotto, Albert ^d   Pagani, Leonardo ^c   Gaillat, Jacques ^c   Forestier, Emmanuel ^g   Gavazzi, Gaëtan ^h  

^a CH Ales CSGA   (France)

^b POITIERS UNIVERSITY HOSPITAL   (France)

^c Centre Hospitalier de la Region d'Annecy   (France)

^d DEPARTMENT OF NEUROLOGY   (France)

^e CH Saumur Geriatric   (France)

^f UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^g CENTRE HOSPITALIER DE CHAMBÉRY   (France)

^h GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Aminoglycoside; Oldest old; Renal failure

Indexed keywords

AMINOGLYCOSIDE; ANTIINFECTIVE AGENT;

AGE; AGED; BACTERIAL INFECTIONS; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG MONITORING; DRUG USE; FEMALE; FRANCE; HUMAN; KIDNEY DISEASES; MALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTICENTER STUDY; RETROSPECTIVE STUDY; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; DRUG UTILIZATION REVIEW; FEMALE; FRANCE; HUMANS; KIDNEY DISEASES; MALE; MICROBIAL SENSITIVITY TESTS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84906886529     PISSN: 00020729     EISSN: 14682834     Source Type: Journal    
DOI: 10.1093/ageing/afu023     Document Type: Article

References (14)

1. Gilbert DN. Aminoglycosides. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 5th edition, New York: Churchill Livingstone, 2000; 307-36.
2. Faulkner CM, Cox HL, Williamson JC. Unique aspects of antimicrobial use in older adults. Clin Infect Dis 2005; 40: 997-1004.
3. Hilmer SN, Tran K, Rubie P, Wright J, Gnjidic D, Mitchell SJ, Matthews S, Carroll PR. Gentamicin pharmacokinetics in old age and frailty. Br J Clin Pharmacol 2011; 71: 224-31.
4. Raveh D, Kopyt M, Hite Y, Rudensky B, Sonnenblick M, Yinnon AM. Risk factors for nephrotoxicity in elderly patients receiving once-daily aminoglycosides. QJM 2002; 95: 291-7.
5. Foltz F, Ducher M, Rougier F, Coudray S, Bourhis Y, Druguet M, Maire P. Efficacy and toxicity of aminoglycoside therapy in the elderly: combined effect of both oncedaily regimen and therapeutic drug monitoring. Pathol Biol 2002; 50: 227-32.
6. Update on good use of injectable aminoglycosides, gentamicin, tobramycin, netilmycin, amikacin. Pharmacological properties, indications, dosage, and mode of administration, treatment monitoring. Med Mal Infect 2012; 42: 301-8.
7. Freeman CD, Nicolau DP, Belliveau PP, Nightingale CH. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother 1997; 39: 677-86.
8. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinin: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-70.
9. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G. National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137-47.
10. The European committee on antimicrobial susceptibility testing. Breakpoint table for interpretation of MICs and zone diameters. Version 3.1, 2013. http//www.eucast.org (31 December 2013, date last accessed).
11. Pagkalis S, Mantadakis E, Mavros MN, Ammari C, Falagas ME. Pharmacological considerations for the proper clinical use of aminoglycosides. Drugs 2011; 71: 2277-94.
12. Taccone FS, Laterre PF, Spapen H, Dugernier T, Delattre I, Layeux B, De Backer D, Wittebole X, Wallemacq P, Vincent JLJacobs F. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care 2010; 14: R53.
13. Boyer A, Gruson D, Bouchet S, Clouzeau B, Hoang-Nam B, Vargas F, Gilles H, Molimard M, Rogues AM, Moore N. Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk. Drug Saf 2013; 36: 217-30.
14. Grob JJ, Mege JL, Follana J, Legre R, Andrac L, Bonerandi JJ. Skin necrosis after injection of aminosides. Arthus reaction, local toxicity, thrombotic process or pathergy? Dermatologica 1990; 180: 258-62.